Patients with/without alloHSCT after blinatumomab
| . | Patients treated with blinatumomab (N = 110) . | |
|---|---|---|
| n . | 95% CI . | |
| Patients with/without alloHSCT after blinatumomab, by CR within the first 2 cycles | ||
| Patients with alloHSCT, n (%) | 56 (50.9) | |
| Patients with CR, n (%) | 68 (61.8) | |
| alloHSCT after CR, n (%)* | 50 (73.5) | 61.4-83.5 |
| No alloHSCT after CR, n (%)* | 18 (26.5) | 16.5-38.6 |
| Patients without CR, n (%) | 25 (22.7) | |
| alloHSCT, n (%)† | 6 (24.0) | 9.4-45.1 |
| No alloHSCT, n (%)† | 19 (76.0) | 54.9-90.6 |
| Patients with/without alloHSCT after blinatumomab, by MRD response within the first 2 cycles | ||
| Patients with alloHSCT, n (%) | 52 (47.3) | |
| Patients with MRD response, n (%) | 57 (51.8) | |
| alloHSCT after MRD response, n (%)‡ | 44 (77.2) | 64.2-87.3 |
| No alloHSCT after MRD response, n (%)‡ | 13 (22.8) | 12.7-35.8 |
| Patients without MRD response, n (%) | 19 (17.3) | |
| alloHSCT, n (%)§ | 8 (42.1) | 20.3-66.5 |
| No alloHSCT, n (%)§ | 11 (57.9) | 33.5-79.7 |
| Patients with alloHSCT after blinatumomab, by tumor burden at baseline | ||
| Patients with <5% blasts and MRD ≥ 10−3 (N = 11)ǁ | 9 (82) | 48.2-97.7 |
| Patients with ≥5% blasts (N = 58)¶ | 36 (62) | 48.4-74.5 |
| . | Patients treated with blinatumomab (N = 110) . | |
|---|---|---|
| n . | 95% CI . | |
| Patients with/without alloHSCT after blinatumomab, by CR within the first 2 cycles | ||
| Patients with alloHSCT, n (%) | 56 (50.9) | |
| Patients with CR, n (%) | 68 (61.8) | |
| alloHSCT after CR, n (%)* | 50 (73.5) | 61.4-83.5 |
| No alloHSCT after CR, n (%)* | 18 (26.5) | 16.5-38.6 |
| Patients without CR, n (%) | 25 (22.7) | |
| alloHSCT, n (%)† | 6 (24.0) | 9.4-45.1 |
| No alloHSCT, n (%)† | 19 (76.0) | 54.9-90.6 |
| Patients with/without alloHSCT after blinatumomab, by MRD response within the first 2 cycles | ||
| Patients with alloHSCT, n (%) | 52 (47.3) | |
| Patients with MRD response, n (%) | 57 (51.8) | |
| alloHSCT after MRD response, n (%)‡ | 44 (77.2) | 64.2-87.3 |
| No alloHSCT after MRD response, n (%)‡ | 13 (22.8) | 12.7-35.8 |
| Patients without MRD response, n (%) | 19 (17.3) | |
| alloHSCT, n (%)§ | 8 (42.1) | 20.3-66.5 |
| No alloHSCT, n (%)§ | 11 (57.9) | 33.5-79.7 |
| Patients with alloHSCT after blinatumomab, by tumor burden at baseline | ||
| Patients with <5% blasts and MRD ≥ 10−3 (N = 11)ǁ | 9 (82) | 48.2-97.7 |
| Patients with ≥5% blasts (N = 58)¶ | 36 (62) | 48.4-74.5 |
Percentage based on 68 patients with CR.
Percentage based on 25 patients without CR.
Percentage based on 57 patients with MRD response.
Percentage based on 19 patients without MRD response.
N is based on the number of patients with <5% blasts and MRD ≥ 10−3 at baseline who achieved CR within the first 2 cycles of blinatumomab.
N is based on the number of patients with ≥5% blasts at baseline who achieved CR within the first 2 cycles of blinatumomab.